The Food and Drug Administration (FDA) has declared that the active ingredient in Eli Lilly's weight loss drug Zepbound is no longer in shortage, effectively preventing compounding pharmacies from producing unbranded versions. However, the FDA will grant a 60 to 90-day transition period during which it will not penalize pharmacies for making compounded tirzepatide, giving patients time to switch to the branded drug. This decision marks the end of a period during which certain pharmacies could compound, distribute, or dispense tirzepatide without facing violations related to the treatment's shortage status.
The Food and Drug Administration said the active ingredient in Eli Lilly's weight loss drug Zepbound is no longer in shortage, a decision that will eventually bar compounding pharmacies from making unbranded versions of the injection.
The FDA said it will provide a 60- to 90-day transition period where it will not take action against pharmacies for making compounded tirzepatide, which will give patients time to switch to the branded version. The U.S. Food and Drug Administration does not review the safety and efficacy of compounded products, and the agency hasFeeling out of the loop? We'll catch you up on the Chicago news you need to know. Sign up for the weekly
FDA Tirzepatide Shortage Compounding Pharmacies Zepbound Mounjaro
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Tirzepatide shows powerful diabetes-prevention effect in three-year trialTirzepatide, a new injectable weight-loss drug, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a three-year period, compared with placebo, according to the results of a new study.
Read more »
Tirzepatide Reduces Circulatory Overload and End-Organ Damage in HFpEF and ObesityA secondary analysis of the SUMMIT trial indicates that tirzepatide, when used in patients with obesity-related heart failure with preserved ejection fraction (HFpEF), decreases blood pressure and blood volume. It also improves cardiovascular function and reduces systemic inflammation.
Read more »
HFpEF Surpasses HFrEF as Most Common Heart Failure Type, Study Reveals Positive Effects of TirzepatideHFpEF has become the most common form of heart failure, surpassing HFrEF. A recent study evaluated the effects of tirzepatide on patients with HFpEF and obesity, showing positive outcomes on heart failure events and functional capacity.
Read more »
How the weight loss drug tirzepatide is also helping heart failure patientsData continue to show that tirzepatide, called Mounjaro for type 2 diabetes and Zepbound for weight loss, is safe and effective, but side effects remain.
Read more »
Lilly invests $3 billion to expand Wisconsin plant as obesity drug demand soarsZepbound and Lilly's diabetes drug Mounjaro, both known chemically as tirzepatide, were in shortage in the U.S. for much of this year.
Read more »
Rangers' win streak ends at three after comeback falls short against FlamesThe Flames came out on top in the third period to hand the Rangers a 3-2 loss and end their three-game win streak.
Read more »